

ORGANIZATIONAL ANNOUNCEMENT

Auro Vaccines



Please help us in congratulating Michael Egan on his promotion!



After a long tenure leading the team at Profectus BioSciences and subsequently Auro Vaccines, John Eldridge, Chief Scientific Officer, will be retiring. We wish him well on his next chapter! With John's departure comes the promotion of Michael Egan, who will now be heading the vaccine division in New York as Chief Scientific Officer, effective Monday August 31, 2020.

Michael joined the Aurobindo Pharma family in January 2020 as Vice President, R&D and Deputy Chief Scientific Officer. In February 2020, when Profectus BioSciences was acquired to form the new vaccine division under the Aurobindo umbrella, Dr. Egan assisted with the transition to ensure a smooth onboarding and flow of information to the team. With over 25 years of experience in the industry and strong leadership capabilities, he is set to make a significant impact on the success of the division as we head into the future.

Prior to coming on board, Dr. Egan held the role of Discovery Project Leader for the Bill and Melinda Gates Medical Research Institute (Gates MRI) where he worked to drive progression of early stage projects and ensure the availability of a continuous pipeline of assets for clinical development. In addition, he previously held leadership roles at both Profectus BioSciences and Wyeth Vaccines Research, overseeing a diverse group of scientists in the research and development of various vaccine candidates through to clinical trials. To his credit, Dr. Egan has 40 publications and served on numerous National Institute of Health scientific review committees.

Dr. Egan received his Ph.D, from Johns Hopkins University School of Medicine in Biochemistry, Cellular and Molecular Biology (BCMB) with emphasis in Immunology and went on to complete his postdoctoral training at Harvard Medical School.